New quadrivalent meningitis vaccine shows promise in large pediatric trial
NCT ID NCT07135986
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 39 times
Summary
This Phase 3 study is testing an investigational meningococcal conjugate vaccine (MenACYW) in over 1,600 healthy children and adolescents aged 2 to 17 in China. The vaccine aims to protect against four types of meningococcal bacteria that can cause serious infections like meningitis. Researchers are comparing the new vaccine's immune response and safety to currently licensed meningococcal vaccines in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 1561000
Nanning, Guangxi, 530028, China
-
Investigational Site Number : 1561001
Jingxi, 533899, China
-
Investigational Site Number : 1561002
Tengzhou, 543399, China
-
Investigational Site Number : 1561003
Liuzhou, 545100, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MenACYW conjugate vaccine (MenQuadfi)
What this could lead to
If successful, this vaccine could provide broader protection against four types of meningococcal bacteria with a single shot, potentially simplifying vaccination schedules for children and teens.
What could go wrong
This is a Phase 3 trial, but it is still testing the vaccine's immune response and safety. The vaccine may not prove superior to existing vaccines, and rare side effects could emerge in larger populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.